InsiderTrades

Form 4 for KNSA Kiniksa Pharmaceuticals International, plc

Accepted 2025-03-24 00:00:00 ET · period of report 2025-03-20 · accession 0001415889-25-008846 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-03-24 2025-03-20 KNSA Ragosa Mark CFO M - OptEx $12.97 +15.9K 39.3K +68% +$206.8K
D 2025-03-24 2025-03-20 KNSA Ragosa Mark CFO S - Sale+OE $23.11 -15.9K 23.4K -41% -$368.5K
D 2025-03-24 2025-03-20 KNSA Ragosa Mark CFO M - OptEx $0.00 -15.9K 8,374 -66% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Ordinary Share 2025-03-20 M A 15,944 $12.97 39,326 D — —
2 Common Class A Ordinary Share 2025-03-20 S D 15,944 $23.11 23,382 D — — (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $23.10 and $23.185. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3 Derivative Share Option 2025-03-20 M D 15,944 $0.00 8,374 D $12.97 · — to 2031-09-01 15,944 Class A Ordinary Share (F3) The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021.